Cancer-Associated Venous Thromboembolism — Beyond 6 Months

This editorial discusses the management of cancer-associated venous thromboembolism (VTE) beyond the standard 6-month anticoagulation period, highlighting the evolving landscape of treatment options. The Apixaban Cancer Associated Thrombosis (API-CAT) trial demonstrated that reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose apixaban (5 mg twice daily) in preventing recurrent VTE while significantly reducing clinically relevant bleeding. The findings support personalized, long-term anticoagulation strategies for cancer patients, emphasizing patient-centered outcomes and quality of life.

This editorial discusses the management of cancer-associated venous thromboembolism (VTE) beyond the standard 6-month anticoagulation period, highlighting the evolving landscape of treatment options. The Apixaban Cancer Associated Thrombosis (API-CAT) trial demonstrated that reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose apixaban (5 mg twice daily) in preventing recurrent VTE while significantly reducing clinically relevant bleeding. The findings support personalized, long-term anticoagulation strategies for cancer patients, emphasizing patient-centered outcomes and quality of life.